Pfizer Grants ChemRar Group Exclusive License to DPP-IVi Type 2 Diabetes Candidate
MOSCOW, Jul 05, 2012 (MARKETWIRE via COMTEX) -- ChemRar Hi-Tech Centre, the Russian pharmaceutical investment and R&D group, announced today that Pfizer granted exclusive development and marketing rights to SatRx for their DPP(1)-IVi compound, PF-00734200. SatRX, a ChemRar group company, is developing PF-00734200 for type 2 diabetes (T2D), one of the most burdensome chronic non-communicable diseases, which is fast reaching epidemic proportions throughout the world.
Under the terms of the license, signed during the St. Petersburg Economic Forum on June 23, Pfizer granted exclusive worldwide rights (ex-China) development and commercialization of PF-00734200 as monotherapy or in combination with certain other. Pfizer will receive royalties and milestone payments based on commercialization activities. The agreement was developed as partial fulfillment of a Memorandum of Understanding reached in March 2011, under which Pfizer and ChemRar agreed to explore collaborations focused on research, development and commercialization of innovative compounds and vaccines to treat cardiometabolic, infectious and oncologic diseases in Russia and other countries.
"We welcome this licensing agreement between SatRx and Pfizer. SatRx is going to register the new drug to the Russian market and will further establish breakthrough therapies for treating diabetes synergistically combining DPP-IVi with TGR5 agonists and other novel small molecule drug candidates in its R&D portfolio. ChemRar is committed to investing in development of innovative medicines, diagnostics and devices to control and treat type 2 and type 1 diabetes," confirmed Nikolay Savchuk, board member of ChemRar HTC. "We aspire to further expand our collaboration with Pfizer in the framework of the MOU we signed in 2011."
"This licensing agreement with Pfizer provides SatRx with essential background for development of fully innovative tools to tune the metabolism of patients with T2D and obesity. Synergistic actions of DPP-IVi and proprietary new SatRx molecules active in the incretin metabolic cascade will provide significant therapeutic benefits and promises to increase patient compliance and quality of life," said Yulia Baybikova, General Manager of SatRx.
The World Health Organization (WHO)(2) considers diabetes among the four most socially significant diseases, along with cardiovascular and respiratory diseases and cancers; responsible for 80% of deaths from non-communicable diseases worldwide. One of ten people in the world has diabetes, and T2D, formerly called non-insulin-dependent or adult-onset diabetes, comprises 90% of those cases.
Based on Russian Endocrinology Association data(3), the prevalence of T2D is increasing in the Russian Federation in parallel with overall global trends. As of January 1, 2011 more than 3.3 million diabetes cases were registered in Russia, and 90% are T2D. Control-and-epidemiological studies by the State Federal Endocrinology Center from 2005-2010 indicate that the number of diabetic patients exceed the number of registered cases by 2-3 times. During the last 10 years the number of patients with diabetes in Russia has doubled.
ChemRar High Tech Center is a unique group of biotech start up, R&D service and venture investment companies developing and commercializing innovative medicines for treatment of cardiometabolic and infectious diseases, oncology, and CNS pathologies in Russia and abroad.
ChemRar Ventures is a Russian venture company, managing a diversified investment portfolio of biopharma, diagnostic and medical device companies developing treatments for unmet medical needs.
SatRx is an R&D company focused on development in the area of diabetes and obesity.
SatRx is a Russian start-up company established in 2010 on the basis of ChemRar High Tech Center which aims to develop novel medicines and their synergistic combinations to treat diabetes, obesity and other metabolic diseases.
(1) DPP4i (dipeptidyl peptidase) inhibitors provide a class of therapies that manage blood-glucose levels without the associated risk of hypoglycaemia that may be experienced with other diabetes medication.
(2) The World health statistics 2012 report
(3) I. Dedov and co-authors, Monograph "Consensus of experts of Russian association of endocrinologists on initiation of intensification of sugar-decreasing treatment for patients with type 2 diabetes", p.7, 2011
+7 (926) 206-78-71
SOURCE: ChemRar Group